TORONTO, April 19, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced today the filing of a new provisional patent application that…

Source

Previous articlePT311 – William Leonard Pickard – LSD, Fentanyl, Prison, and the Greatest Gift of All: The Natural Mind
Next articlePT312 – Deborah Snyder – Ecology, Synergy, and the Biosphere